ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.
India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology.
Alzheimer’s disease is a devastating brain disorder that now affects about 5.3 million Americans, accounting for one in nine people over the age of 65, according to the Alzheimer’s Association.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is offering a unique opportunity for investors as the company pursues a multi-pronged approach to conquering the rapidly expanding global markets in cannabidiol products and the medical marijuana space in Canada. The company aims to be the world’s leading publicly traded Chinese nutritional company.
India Globalization Capital, Inc. (NYSE MKT: IGC) has set a long-term goal for itself in the U.S. of becoming a leading provider of cannabis-based pharmaceutical and nutraceutical products.
One of the very first licensed producers and a pioneer in Canadian medical cannabis, ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) has always held to meticulous specifications in the production of its pharmaceutical grade, plant-based medicines.
Cannabidiol (CBD) has been scientifically shown to be effective in the treatment of certain epilepsies, pain, inflammation and nausea, as well as providing relief from hangover, anxiety and stress.
Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses.
India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments.
The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use.
Various public companies are accomplishing the two-fold mission of improving the health of our four-footed friends while giving investors the opportunity to capitalize on a multibillion-dollar industry.
Combination therapies that use cannabis-based pain reduction methods without the negative side effects of opioids are looking to be a positive growth opportunity among specialty pharmaceuticals, particularly for postoperative and chronic pain relief.
How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions?